7.78
+0.42(+5.71%)
Currency In USD
| Previous Close | 7.36 |
| Open | 7.45 |
| Day High | 8 |
| Day Low | 7.43 |
| 52-Week High | 11.78 |
| 52-Week Low | 2.22 |
| Volume | 57,903 |
| Average Volume | 172,788 |
| Market Cap | 86.41M |
| PE | -12.35 |
| EPS | -0.63 |
| Moving Average 50 Days | 5.07 |
| Moving Average 200 Days | 5.37 |
| Change | 0.42 |
If you invested $1000 in Nutriband Inc. (NTRB) since IPO date, it would be worth $1,355.4 as of February 05, 2025 at a share price of $7.78. Whereas If you bought $1000 worth of Nutriband Inc. (NTRB) shares 3 years ago, it would be worth $1,892.94 as of February 05, 2025 at a share price of $7.78.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nutriband Issues Letter to Shareholders
GlobeNewswire Inc.
Dec 31, 2024 12:00 PM GMT
ORLANDO, Fla., Dec. 31, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders highlighting the company’s achievements in 2024 and the outlook for 2025.
Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal Technology
GlobeNewswire Inc.
Dec 27, 2024 2:25 PM GMT
Nutriband’s abuse-deterrent platform technology is now patented in 46 countries and territories covering major global markets. Nutriband is targeting to file for FDA approval for AVERSA™ Fentanyl in the first half of 2025. ORLANDO, Fla., Dec. 27, 20
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025
GlobeNewswire Inc.
Dec 04, 2024 2:00 PM GMT
ORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today reported its financial results for the third quarter ended October 31, 2024. The Company reported a strong cash position at quarter end, reinforcing